Dynavax Technologies Long Term Debt 2010-2025 | DVAX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Dynavax Technologies long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Dynavax Technologies long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$245.4B
Amgen (AMGN)	$157.5B
Gilead Sciences (GILD)	$146.4B
Vertex Pharmaceuticals (VRTX)	$100B
Bristol Myers Squibb (BMY)	$98.1B
CSL (CSLLY)	$85.5B
GSK (GSK)	$79.6B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$59.9B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$26.9B
Royalty Pharma (RPRX)	$20.9B
Biogen (BIIB)	$19.9B
Incyte (INCY)	$16.6B
Illumina (ILMN)	$15.5B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11B
Moderna (MRNA)	$10.9B
QIAGEN (QGEN)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Halozyme Therapeutics (HALO)	$8.1B
Roivant Sciences (ROIV)	$8B